Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation.
Exclusive enteral nutrition using polymeric formula (PF) is a well-established therapeutic option for active Crohn's disease; however, its mechanisms of action are unknown. We investigated the anti-inflammatory effects of PF in an in vitro model of epithelial cell inflammation. PF did not affect cell viability over a range of dilutions, but when PF was added to the culture medium the interleukin (IL)-8 response to proinflammatory stimuli was significantly reduced. This effect was due to PF acting directly on the cells as the IL-8 response was still reduced when PF was separated from the proinflammatory stimuli in a 2-compartment system. In the presence of PF, nuclear factor (NF)-kappaB nuclear migration was not inhibited; however, IkappaBalpha degradation was delayed. PF has direct anti-inflammatory effects upon immortalized colonic enterocytes. Therefore PF may, in part, modulate gut inflammation by directly reducing the inflammatory response of the intestinal epithelium.
de Jong
Naomi S H
NS
School of Women's and Children's Health, University of New South Wales, Sydney, Australia.
Leach
Steven T
ST
Day
Andrew S
AS
D015153:Blotting, Western; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003470:Culture Media; D004338:Drug Combinations; D020895:Enterocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D019073:HT29 Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D053582:Interleukin-1alpha / Q000627:therapeutic use*; D016209:Interleukin-8 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000627:therapeutic use*; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D051996:Transcription Factor RelA / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D003470:Culture Media; D004338:Drug Combinations; D007074:Immunoglobulin G; D053582:Interleukin-1alpha; D016209:Interleukin-8; D008070:Lipopolysaccharides; D016328:NF-kappa B; C093394:TONSL protein, human; D051996:Transcription Factor RelA; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha